Indivior Pharmaceuticals (INDV) Depreciation & Amortization (CF) (2022 - 2026)
Indivior Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 5 years, most recently at $2.0 million for Q1 2026.
- For Q1 2026, Depreciation & Amortization (CF) fell 33.33% year-over-year to $2.0 million; the TTM value through Mar 2026 reached $9.0 million, down 43.75%, while the annual FY2025 figure was $10.0 million, 37.5% down from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 was $2.0 million at Indivior Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $6.0 million in Q3 2023 and troughed at $2.0 million in Q4 2023.
- A 5-year average of $3.6 million and a median of $4.0 million in 2022 define the central range for Depreciation & Amortization (CF).
- Biggest five-year swings in Depreciation & Amortization (CF): tumbled 60.0% in 2023 and later soared 150.0% in 2024.
- Year by year, Depreciation & Amortization (CF) stood at $5.0 million in 2022, then tumbled by 60.0% to $2.0 million in 2023, then soared by 150.0% to $5.0 million in 2024, then tumbled by 60.0% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
- Business Quant data shows Depreciation & Amortization (CF) for INDV at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $2.0 million in Q3 2025.